Conference
Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns?
Abstract
327
Background: FOLFIRINOX (FFX), gemcitabine+nab-paclitaxel (GnP) and gemcitabine monotherapy (Gem)) are universally funded as first-line chemotherapy regimens for advanced pancreatic cancer (APC) in Ontario, Canada. However, there is scarce real-world data on factors that may influence choice of chemotherapy regimens in APC. Methods: Patients who received first-line chemotherapy for APC between April 2015-March 2016 in …
Authors
Raskin W; Guo H; Beca JM; Isaranuwatchai W; Qiao L; Earle C; Berry SR; Biagi JJ; Welch S; Meyers BM
Volume
36
Pagination
pp. 327-327
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2018
DOI
10.1200/jco.2018.36.4_suppl.327
Conference proceedings
Journal of Clinical Oncology
Issue
4_suppl
ISSN
0732-183X